Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19
A Phase I/II Single-Blinded Randomized Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of COVID 19
Sponsor: AstraZeneca
This PHASE1/PHASE2 trial investigates COVID-19 and is currently completed. AstraZeneca leads this study, which shows 9 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Oct 2021 — Jul 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 4 earlier versions
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Feb 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- R-Pharm
- Russian Direct Investment Fund
- The Gamaleya National Center of Epidemiology & Microbiology
For direct contact, visit the study record on ClinicalTrials.gov .